Anlon Healthcare Intrinsic Value
Anlon Healthcare (AHCL) median intrinsic value is ₹43.89 from 8 valuation models (range ₹29–₹44), vs current price ₹14.63 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. Analyse Anlon Healthcare ownership pattern to track promoter, FII and institutional holdings.
AHCL Valuation Methods Summary — DCF, Graham Number & P/E
Anlon Healthcare intrinsic value across 8 models vs current price ₹14.63 — upside/downside and value range per method. Read AHCL dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹43.89 | ₹35.11 - ₹52.67 | +200.0% | EPS: ₹9.32, Sector P/E: 22x |
| Book Value Method | asset | ₹36.58 | ₹32.92 - ₹40.24 | +150.0% | Book Value/Share: ₹39.62, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹29.26 | ₹26.33 - ₹32.19 | +100.0% | Revenue/Share: ₹38.49, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹29.26 | ₹26.33 - ₹32.19 | +100.0% | EBITDA: ₹60.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹43.89 | ₹39.50 - ₹48.28 | +200.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹43.89 | ₹39.50 - ₹48.28 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹29.26 | ₹26.33 - ₹32.19 | +100.0% | ROE: 21.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹43.89 | ₹39.50 - ₹48.28 | +200.0% | EPS: ₹9.32, BVPS: ₹39.62 |
AHCL Intrinsic Value vs Market Price — All Valuation Models
Anlon Healthcare fair value range ₹29–₹44 vs current market price ₹14.63 across 8 valuation models. For current market price and key ratios, visit AHCL share price.
AHCL Intrinsic Value Analysis — Undervalued or Overvalued?
Anlon Healthcare median intrinsic value ₹43.89, current price ₹14.63 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of AHCL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Anlon Healthcare (AHCL) is ₹43.89 (median value). With the current market price of ₹14.63, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹29.26 to ₹43.89, indicating ₹29.26 - ₹43.89.
Is AHCL undervalued or overvalued?
Based on our multi-method analysis, Anlon Healthcare (AHCL) appears to be trading below calculated value by approximately 200.0%.
AHCL Financial Health — Key Ratios vs Industry Benchmarks
Anlon Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 37.14 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.64x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AHCL Cash Flow Quality — Operating & Free Cash Flow
Anlon Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-23 Cr | ₹-23 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-3 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-15 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |